MedTrace Logo

Filter Lifespan in Continuous Renal Replacement Therapy

NCT05450185 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-12-12

No results posted yet for this study

Summary

The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.

Conditions

  • Critically Ill
  • Continuous Renal Replacement Therapy
  • Infections

Interventions

PROCEDURE

Critically ill patients with continuous renal replacement therapy

Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.

Sponsors & Collaborators

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Alexander Zarbock, MD · University Hospital Münster

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-02
Primary Completion
2025-05-31
Completion
2025-08-31

Countries

  • Austria
  • Brazil
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05450185 on ClinicalTrials.gov